GLM models for predictors of monthly HTN care costs. by Drew B. Cameron (10687420)

Subjects:

Median monthly care costs, projected visits, and hospitalization costs. by Drew B. Cameron (10687420)

Subjects:

Average stability values (mean ± standard deviation) and statistical results. by Hyung Suk Yang (20442438)

Subjects:

Stability differences between condition 1 and other conditions across participants on the non-hemiparetic side (NHP) side. by Hyung Suk Yang (20442438)

Subjects:

Individual stability values for different gait events under various conditions. by Hyung Suk Yang (20442438)

Subjects:

Dynamic stability based on the Feasible Stability Region (FSR). by Hyung Suk Yang (20442438)

Subjects:

Stability differences between condition 1 and other conditions across participants on the hemiparetic (HP) side. by Hyung Suk Yang (20442438)

Subjects:

Periodic Open Cellular Structures with Streamlined Elliptical Struts for the Intensification of Mass Transfer-Limited Catalytic Reactors by Claudio Ferroni (10972436)

Subjects:

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

Subjects:

Flow diagram of different experiments and the study process. by Omid Mehrpour (9385929)

Subjects:

The mean scores of epidermis and dermis healing processes in burned rats after 10 and 21 days treatment with silver sulfadiazine 1% (silver), opium 0.05% (OP 0.05%), opium 0.5% (OP... by Omid Mehrpour (9385929)

Subjects:

The representative histological images of rat deep partial-thickness burns after 10 and 21 days of treatment with silver sulfadiazine 1% (SSD), opium 0.05% (OP0.05%), opium 0.5% (O... by Omid Mehrpour (9385929)

Subjects:

The concentration of inflammatory parameters (TNF-α and IL-10) in serum (a and b) and burned skin samples (c) of different experimental groups on day 2 and 10. by Omid Mehrpour (9385929)

Subjects:

The wound appearance of different groups during the period of study (a) and the percentage of wound reduction in treated groups on different days (b). by Omid Mehrpour (9385929)

Subjects: